Search research articles
Contact Us
Filters
Showing results (41-50 of 97) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castration
A Dupont, H Boucher, L Cusan, et al.
The American Journal of Medicine
|
May 1, 1992
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report
J L Gomez, A Dupont, L Cusan, et al.
Endocrinology
|
August 1, 1978
Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, Des-Gly-NH210] LHRH ethylamide
G Pelletier, L Cusan, C Auclair, et al.
Journal of the American Academy of Dermatology
|
September 1, 1990
Treatment of hirsutism with the pure antiandrogen flutamide
L Cusan, A Dupont, A Bélanger, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 5, 1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
F Labrie, P Diamond, L Cusan, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 14, 2007
Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women
F Labrie, A Bélanger, C Labrie, et al.
Molecular and Cellular Endocrinology
|
January 1, 1981
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat
C Séguin, L Cusan, A Bélanger, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
October 1, 1990
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report
F Labrie, A Dupont, A Bélanger, et al.
Anticancer Research
|
March 1, 1994
Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide)
M Koutsilieris, A Dupont, J Gomez, et al.
L'Union Medicale Du Canada
|
April 1, 1978
[Inhibition of gonadal function by LHRH and their agonists in the male and female rat]
C Auclair, L Cusan, G S Kledzik, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 97) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1990
Octreotide and bromocriptine in patients with stage D2 prostate cancer who relapsed during treatment with flutamide and castration
A Dupont, H Boucher, L Cusan, et al.
The American Journal of Medicine
|
May 1, 1992
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report
J L Gomez, A Dupont, L Cusan, et al.
Endocrinology
|
August 1, 1978
Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, Des-Gly-NH210] LHRH ethylamide
G Pelletier, L Cusan, C Auclair, et al.
Journal of the American Academy of Dermatology
|
September 1, 1990
Treatment of hirsutism with the pure antiandrogen flutamide
L Cusan, A Dupont, A Bélanger, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 5, 1997
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
F Labrie, P Diamond, L Cusan, et al.
The Journal of Steroid Biochemistry and Molecular Biology
|
July 14, 2007
Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women
F Labrie, A Bélanger, C Labrie, et al.
Molecular and Cellular Endocrinology
|
January 1, 1981
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat
C Séguin, L Cusan, A Bélanger, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
October 1, 1990
Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report
F Labrie, A Dupont, A Bélanger, et al.
Anticancer Research
|
March 1, 1994
Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal treatment (GnRH-A plus flutamide)
M Koutsilieris, A Dupont, J Gomez, et al.
L'Union Medicale Du Canada
|
April 1, 1978
[Inhibition of gonadal function by LHRH and their agonists in the male and female rat]
C Auclair, L Cusan, G S Kledzik, et al.
Page
of 10